NASDAQ: AARD
Aardvark Therapeutics Inc Stock Ownership - Who owns Aardvark Therapeutics?

Insider buying vs selling

Have Aardvark Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Cormorant Asset Management LPInsider2025-02-14187,500$16.00
$3.00MBuy
Decheng Capital Global Life Sciences Fund IV LP10% Owner2025-02-14625,000$16.00
$10.00MBuy
Decheng Capital Global Life Sciences Fund IV LP10% Owner2025-02-14625,000$16.00
$10.00MBuy
Tienli LeeChief Executive Officer2025-02-1416,542$16.00
$264.67kBuy
Nelson SunChief Financial Officer2025-02-1410,000$16.00
$160.00kBuy

1 of 1

AARD insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when AARD insiders and whales buy or sell their stock.

AARD Shareholders

What type of owners hold Aardvark Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Decheng Capital LLC18.06%3,917,299$42.07MInstitution
Decheng Capital Global Life Sciences Fund IV LP18.06%3,917,299$42.07MInsider
Tienli Lee13.69%2,970,203$31.90MInsider
Vickers Venture Fund VI Pte Ltd9.45%2,050,902$22.03MInsider
Citadel Advisors LLC5.87%1,274,084$13.68MInstitution
Cormorant Asset Management LP4.55%987,689$10.61MInsider
Laurion Capital Management LP3.73%808,243$8.68MInstitution
Cormorant Asset Management LP3.69%800,189$8.59MInstitution
Braidwell LP2.30%500,000$5.37MInstitution
Suvretta Capital Management LLC1.44%312,500$3.36MInstitution

1 of 3

AARD vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
AARD40.04%46.82%Net Buying
TNXP3.05%96.95%Net BuyingNet Buying
TVRD2.01%97.99%Net Selling
TVGN2.09%85.17%Net SellingNet Selling
FHTX72.51%14.32%Net Selling

Aardvark Therapeutics Stock Ownership FAQ

Who owns Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ: AARD) is owned by 40.04% institutional shareholders, 46.82% Aardvark Therapeutics insiders, and 13.14% retail investors. Decheng Capital Global Life Sciences Fund IV LP is the largest individual Aardvark Therapeutics shareholder, owning 3.92M shares representing 18.06% of the company. Decheng Capital Global Life Sciences Fund IV LP's Aardvark Therapeutics shares are currently valued at $42.07M.

If you're new to stock investing, here's how to buy Aardvark Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.